AIM: To evaluate the utility of gold nanorods (AuNRs) as a contrast agent for ocular optical coherence tomography (OCT). METHODS: Mice were intravitreally injected with sterile AuNRs coated with either poly(strenesulfate) (PSS-AuNRs) or anti-CD90.2 antibodies (Ab-AuNRs), and imaged using OCT. After 24 h, eyes were processed for transmission electron microscopy or rendered into single cell suspensions for flow cytometric analysis to determine absolute numbers of CD45(+) leukocytes and subsets (T cells, myeloid cells, macrophages, neutrophils). Generalised estimation equations were used to compare cell counts between groups. RESULTS: PSS-AuNRs and Ab-AuNRs were visualised in the vitreous 30 min and 24 h post-injection with OCT. At 24 h, a statistically significant increase in leukocytes, comprised primarily of neutrophils, was observed in eyes that received either AuNR in comparison to eyes that received saline. The accumulation of leukocytes was equal in eyes given PSS-AuNR or Ab-AuNR. Endotoxin-resistant C3H/HeJ mice also showed ocular inflammation after injection with AuNRs, indicating that the inflammatory response was not due to lipopolysaccharide contamination of AuNRs. CONCLUSIONS: Although AuNRs can be visualised in the eye using OCT, they can induce ocular inflammation, which limits their use as a contrast agent.
AIM: To evaluate the utility of gold nanorods (AuNRs) as a contrast agent for ocular optical coherence tomography (OCT). METHODS:Mice were intravitreally injected with sterile AuNRs coated with either poly(strenesulfate) (PSS-AuNRs) or anti-CD90.2 antibodies (Ab-AuNRs), and imaged using OCT. After 24 h, eyes were processed for transmission electron microscopy or rendered into single cell suspensions for flow cytometric analysis to determine absolute numbers of CD45(+) leukocytes and subsets (T cells, myeloid cells, macrophages, neutrophils). Generalised estimation equations were used to compare cell counts between groups. RESULTS:PSS-AuNRs and Ab-AuNRs were visualised in the vitreous 30 min and 24 h post-injection with OCT. At 24 h, a statistically significant increase in leukocytes, comprised primarily of neutrophils, was observed in eyes that received either AuNR in comparison to eyes that received saline. The accumulation of leukocytes was equal in eyes given PSS-AuNR or Ab-AuNR. Endotoxin-resistant C3H/HeJmice also showed ocular inflammation after injection with AuNRs, indicating that the inflammatory response was not due to lipopolysaccharide contamination of AuNRs. CONCLUSIONS: Although AuNRs can be visualised in the eye using OCT, they can induce ocular inflammation, which limits their use as a contrast agent.
Authors: Alex W H Lin; Nastassja A Lewinski; Jennifer L West; Naomi J Halas; Rebekah A Drezek Journal: J Biomed Opt Date: 2005 Nov-Dec Impact factor: 3.170
Authors: Anant Agrawal; Stanley Huang; Alex Wei Haw Lin; Min-Ho Lee; Jennifer K Barton; Rebekah A Drezek; T Joshua Pfefer Journal: J Biomed Opt Date: 2006 Jul-Aug Impact factor: 3.170
Authors: A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler Journal: Science Date: 1998-12-11 Impact factor: 47.728
Authors: Debasish Sen; Elliott D SoRelle; Orly Liba; Roopa Dalal; Yannis M Paulus; Tae-Wan Kim; Darius M Moshfeghi; Adam de la Zerda Journal: J Biomed Opt Date: 2016-06-01 Impact factor: 3.170
Authors: Hardik A Parikh; Ralitsa T Loewen; Pritha Roy; Joel S Schuman; Kira L Lathrop; Nils A Loewen Journal: Sci Rep Date: 2016-11-04 Impact factor: 4.379
Authors: Bo Wang; Larry Kagemann; Joel S Schuman; Hiroshi Ishikawa; Richard A Bilonick; Yun Ling; Ian A Sigal; Zach Nadler; Andrew Francis; Michelle G Sandrian; Gadi Wollstein Journal: PLoS One Date: 2014-03-03 Impact factor: 3.240
Authors: Ralitsa T Loewen; Eric N Brown; Pritha Roy; Joel S Schuman; Ian A Sigal; Nils A Loewen Journal: PLoS One Date: 2016-03-21 Impact factor: 3.240
Authors: Ralitsa T Loewen; Eric N Brown; Gordon Scott; Hardik Parikh; Joel S Schuman; Nils A Loewen Journal: Invest Ophthalmol Vis Sci Date: 2016-05-01 Impact factor: 4.799